Breast Cancer Trials / Trials in New Mexico
36 Recruiting Trials

Clinical Trials
for Breast Cancer in New Mexico

36 clinical trials for Breast Cancer are currently recruiting participants at study sites in New Mexico. Study-related care is provided at no cost.

36
Recruiting trials
37
Study sites
5
Cities
23
Industry-sponsored
7
Phase 2
18
Phase 3

Breast Cancer clinical trials in New Mexico: what to expect

Breast cancer trials are sorted first by subtype, because the treatments differ: hormone-receptor-positive, HER2-positive (including the newer HER2-low group) and triple-negative disease each have their own studies. Most recruiting trials test a new drug or combination, including targeted pills, antibody-drug conjugates and immunotherapy, either for metastatic cancer or before and after surgery for early-stage disease. Others study less surgery or radiation, ways to reduce recurrence, and screening for people at higher risk.

In New Mexico, recruiting breast cancer studies are concentrated in Albuquerque, Rio Rancho, Santa Fe and Las Cruces, with sites in 1 other city. 23 of the 36 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who breast cancer trials usually look for

Listings name the subtype, the stage (early or metastatic) and how many treatments you may already have had. Early-stage trials often enroll between diagnosis and surgery, or in the months after surgery; metastatic trials usually enroll when a treatment has stopped working. Some specify menopausal status or a particular mutation (BRCA, PIK3CA, ESR1), which the site can test for. Nearly all require that you are well enough for daily activity and that recent blood work is adequate.

Your receptor status is on your pathology report; the site will confirm it from that report, so you do not need to know it by heart to ask.

What taking part involves

Screening reviews your pathology and scans and adds blood work, sometimes a biopsy. Treatment then runs in cycles, with infusions every two to three weeks or daily pills, and scans every two to three months to check the response. Early-stage trials follow you for years after treatment ends, usually with a visit or call every few months. Study drugs and study-specific tests are free; care you would receive anyway is billed to insurance as usual. Placebo, when used, is added to standard treatment.

Questions worth asking the study team

How the study treatment compares with what your oncologist would otherwise recommend; whether the trial is randomized and what the other arm receives; what happens if the cancer grows or returns; and how visits fit around work and family. Many trials now allow some visits at a local clinic.

Showing 20 of 36 recruiting Breast Cancer trials in New Mexico

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
PHASE3 Jonesboro, Arkansas +4 sites NCT06757634
This trial is looking for adults with advanced breast cancer that is HR-positive and HER2-negative. Participants will receive treatment involving gedatolisib along with other medications.
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
PHASE3 Daphne, Alabama +4 sites NCT06103864
This trial is looking for patients with a specific type of breast cancer that is not treatable by surgery. Participants will receive a treatment called Dato-DXd, with or without another drug, or a standard chemotherapy treatment.
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
PHASE3 Hot Springs, Arkansas +4 sites NCT07085767
This trial is looking for adults with advanced breast cancer that hasn’t been treated before. Participants will receive palazestrant with ribociclib or letrozole with ribociclib to see which treatment works better.
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
PHASE3 Daphne, Alabama +4 sites NCT06492616
This trial is looking for women and men with early breast cancer that has a high risk of coming back. Participants will compare the effects of elacestrant with standard treatment after being on another therapy for a while.
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3 Birmingham, Alabama +4 sites NCT05879926
This trial is looking for premenopausal women with early-stage breast cancer that is hormone receptor-positive. Participants will receive hormone therapy and may also get chemotherapy to see if it helps them live longer without cancer returning.
Recruiting
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
PHASE2 Long Beach, California +4 sites NCT07102381
This trial is looking for people with early-stage HER2-positive breast cancer to see if zanidatamab combined with chemotherapy is safe and effective. Participants will need to undergo surgery after the treatment.
Recruiting
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
NA Los Angeles, California +4 sites NCT06896474
This trial is looking for women aged 70 and older diagnosed with early-stage breast cancer. Participants will share their experiences and help improve treatment decisions with their surgeons.
Recruiting
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
PHASE1 Phoenix, Arizona +4 sites NCT06590857
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT05827081
This trial is looking for adults with early breast cancer that is hormone receptor positive and HER2 negative. If you join, you will receive ribociclib along with standard hormone therapy to see how effective this combination is.
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
PHASE3 Birmingham, Alabama +4 sites NCT05774951
This trial is looking for people with early breast cancer who have completed at least 2 years of standard treatment. Participants will receive camizestrant to see if it helps improve their outcomes compared to standard therapy.
Recruiting
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
PHASE1 Hot Springs, Arkansas +4 sites NCT07310420
This trial is looking for premenopausal women aged 18 to 55 who have been diagnosed with early or advanced hormone receptor positive breast cancer. Participants will receive ZOLADEX to help assess ovarian suppression.
Recruiting
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
PHASE3 Birmingham, Alabama +4 sites NCT04852887
This trial is looking for women with early-stage hormone-sensitive breast cancer who are interested in taking part in a study on surgery and hormone therapy without radiation. Participants will need to meet specific health criteria to join.
Recruiting
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
PHASE3 Jonesboro, Arkansas +4 sites NCT07391774
This trial is looking for women who are postmenopausal and have high stage breast cancer that is less likely to come back. Participants will compare hormone therapy and ribociclib to chemotherapy followed by hormone therapy and ribociclib.
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
PHASE3 Birmingham, Alabama +4 sites NCT05633654
This trial is looking for adults with triple negative breast cancer that remains after surgery and treatment. Participants will receive an experimental treatment combining two medications after recovery from surgery.
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
PHASE3 Mobile, Alabama +4 sites NCT06393374
This trial is looking for adults with a specific type of breast cancer called triple-negative breast cancer who didn’t have a full response to their initial treatment. They need to have recently had surgery and recovered well, and they should not have certain complicated health issues like severe nerve pain or a known genetic mutation linked to breast cancer. Additionally, the trial is not for people who have serious eye problems or are currently pregnant or breastfeeding.
Recruiting
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
PHASE3 Chandler, Arizona +4 sites NCT06377852
This trial is looking for older patients with metastatic breast cancer to test different dosing strategies for two medications. Participants will help researchers understand how well these strategies work and which might be better tolerated.
Recruiting
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
PHASE3 Phoenix, Arizona +4 sites NCT06876714
This trial is looking for adults with HER2-positive breast cancer who have no residual invasive disease after chemotherapy. Participants will receive either 6 or 12 months of HER2-targeted medications to see which duration works best.
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
PHASE3 Birmingham, Alabama +4 sites NCT05812807
This trial is looking for people with early-stage triple-negative breast cancer who had no cancer left after previous treatments. Participants will either continue receiving pembrolizumab or just be monitored after surgery to see which approach works better to prevent cancer from coming back.
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
PHASE3 Scottsdale, Arizona +4 sites NCT05696626
This trial is looking for men and women with advanced breast cancer that expresses estrogen receptors and has a specific genetic mutation. Participants will receive either lasofoxifene or fulvestrant along with another drug called abemaciclib.
Recruiting
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NA Anchorage, Alaska +4 sites NCT03723928
This trial is looking for women with hormone receptor positive, HER2 negative metastatic breast cancer. Participants will be monitored using specific blood tests and imaging to check how well their cancer treatment is working.
Recruiting
See all 36 Breast Cancer trials in New Mexico

Where the Breast Cancer studies are in New Mexico

Research sites running the most studies
  • University of New Mexico Cancer Center, Albuquerque9 trials
  • Presbyterian Kaseman Hospital, Albuquerque7 trials
  • Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho6 trials
  • Lovelace Women's Hospital, Albuquerque2 trials
  • Memorial Medical Center-Las Cruces, Las Cruces2 trials
  • Research Site, Albuquerque2 trials
By city

Counts are recruiting studies listing at least one site in New Mexico, from ClinicalTrials.gov, refreshed every two days.

Breast Cancer clinical trials in New Mexico: common questions

How many Breast Cancer clinical trials are recruiting in New Mexico?
TrialFinder currently lists 36 recruiting Breast Cancer clinical trials with study sites in New Mexico. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Breast Cancer clinical trials located in New Mexico?
Sites for these Breast Cancer trials are spread across New Mexico. Open any trial to see its full list of participating locations and contact details.
Do I need insurance to join a Breast Cancer clinical trial in New Mexico?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Breast Cancer trials in New Mexico also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Breast Cancer clinical trial in New Mexico?
Each study sets its own criteria based on age, Breast Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Do I need to know my receptor status to join a breast cancer trial?
It helps, because trials are organized by subtype, but the study site reads it from your pathology report. If a trial needs a test you have not had, such as HER2-low or a BRCA result, the site arranges it.
Are there trials for early-stage breast cancer?
Yes. Early-stage trials enroll before surgery, after surgery, or during the years of hormone therapy that follow, and test ways to lower the chance the cancer returns. The listing says which window it enrolls in.
Will a trial replace the treatment my oncologist planned?
Sometimes it is the plan, with a new drug added or compared; sometimes it is an alternative to discuss. Bring the trial page to your oncologist, who can refer you to the site or advise on timing.
Breast Cancer Trials in Other States
Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming
Helpful Reading
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Breast Cancer trials near you in New Mexico.

Get Matched — Free
No insurance required
About Breast Cancer Trials

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Breast Cancer trials →
Other Conditions in New Mexico
Diabetes Cancer Depression Anxiety Alzheimer's Heart Disease Asthma Multiple Sclerosis Obesity Parkinson's Lupus Hypertension COPD Stroke Arthritis Kidney Disease COVID-19
All trials in New Mexico →